One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration

Published:2023-08 Issue: Volume:Volume 17 Page:2201-2208
ISSN:1177-5483
Container-title:Clinical Ophthalmology
language:en
Short-container-title:OPTH

Author:

Rush Ryan B^ORCID

Publisher

Informa UK Limited

Subject

Ophthalmology

Reference18 articles.

1. Ranibizumab for Neovascular Age-Related Macular Degeneration

2. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

3. Myositis Ossificans

4. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

5. Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short-term results with faricimab in neovascular age-related macular degeneration resistant to both ranibizumab and aflibercept;AJO International;2024-10

2. Short-Term Clinical Outcomes of Patients with Diabetic Macular Edema Following a Therapy Switch to Faricimab;Journal of Clinical Medicine;2024-08-01

3. Short-Term Comparison of Switching to Brolucizumab or Faricimab from Aflibercept in Neovascular AMD Patients;Medicina;2024-07-19

4. Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review;International Journal of Retina and Vitreous;2024-07-12

5. Real-World 1-Year Outcomes of Treatment-Intensive Neovascular Age-Related Macular Degeneration Switched to Faricimab;Ophthalmology Retina;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3